In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...

In fact, AbbVie reported a $4.6 billion loss in ... That pattern was attenuated by the success of its Covid-19 vaccine, which Pfizer produced in the United States for the United States and many ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Medical-device maker Stryker on Monday agreed to acquire Inari Medical , which makes devices that treat patients with venous ...

That said, noted vaccine skeptic Robert F ... Pfizer—which has taken flak for failing to make good on its immense COVID-19 profits—is expected to slip in the rankings of top drugmakers ...

BioNTech, which became a household name when it partnered with Pfizer to develop a Covid-19 vaccine, is now making ... according to Jefferies. AbbVie’s experimental drug Rinvoq to treat in ...

Editor’s Note: The Business Journal this week is honoring Gavin Herbert with our first ever Lifetime Achievement Recognition.

General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

No scientific studies have established a causal relationship between the Pfizer vaccine and conditions that cause the excessive growth of breasts.

Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.